CH
RANI icon

Canton Hathaway’s Rani Therapeutics RANI Stock Holding History

Canton Hathaway’s Portfolio RANI Stock Details RANI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-14,600
Closed -$86K – 246
2022
Q4 		$86K Sell
14,600
-1,600
-10% -$11.7K 0.03% 124
2022
Q3 		$155K Buy
16,200
+7,600
+88% +$80.6K 0.06% 108
2022
Q2 		$89K Buy
+8,600
New +$98.7K 0.03% 128
2022
Q1 		– Sell
-5,000
Closed -$82K – 282
2021
Q4 		$82K Sell
5,000
-5,000
-50% -$114K 0.02% 150
2021
Q3 		$178K Buy
+10,000
New +$173K 0.05% 116

Other funds holding RANI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return
USAA
United Services Automobile Association San Antonio, Texas $851M AUM 5.13% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
ASGS
Alpha Square Group S New York $103M AUM 63.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LM
Lasry Marc $15.1M AUM 10.39% 1-Year Est. Return

Canton Hathaway's RANI Position: Q1 2023 in Review

Canton Hathaway sold out of Rani Therapeutics (RANI) in Q1 2023, closing a stake of 14,600 shares — an estimated $86K sold.

Canton Hathaway first reported a position in RANI in Q3 2021 and held it in 5 quarters. The position peaked at $178K in Q3 2021. 36 funds tracked by Wall St. Rank hold RANI as of Q1 2023.

  • Canton Hathaway reported no remaining Rani Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Canton Hathaway sold 14,600 Rani Therapeutics shares in Q1 2023, an estimated $86K.
  • Canton Hathaway first reported a position in Rani Therapeutics in Q3 2021 and held it in 5 quarters.
  • Canton Hathaway's Rani Therapeutics position peaked at $178K in Q3 2021.
  • 36 funds tracked by Wall St. Rank held Rani Therapeutics as of Q1 2023.

Based on Canton Hathaway's 13F filing for Q1 2023, filed 11 Apr 2023.